Cardiac allograft immune activation: current perspectives

References

• Adler ED, Goldfinger JZ, Kalman J, Park ME, Meier DE. Palliative care in the treatment of advanced heart failure. Circulation. 2009; 120:2597–2606.
   PubMed Web of Science ®Google Scholar
• Rose EA, Gelijns AC, Moskowitz AJ, et al; Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345:1435–1443.
   PubMed Web of Science ®Google Scholar
• Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report – 2011. J. Heart Lung Transplant. 2011;30:1078–1094.
   PubMed Web of Science ®Google Scholar
• Reed EF, Demetris AJ, Hammond E, et al; International Society for Heart and Lung Transplantation. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant. 2006;25(2):153–159.
   PubMed Web of Science ®Google Scholar
• Benichou G, Tonsho M, Tocco G, Nadazdin O, Madsen JC. Innate immunity and resistance to tolerogenesis in allotransplantation. Front Immunol. 2012;3:73.
   PubMed Web of Science ®Google Scholar
• Vallejo JG. Role of toll-like receptors in cardiovascular diseases. Clin Sci (Lond). 2011;121(1):1–10.
   PubMed Web of Science ®Google Scholar
• Asea A. Heat shock proteins and toll-like receptors. In: Bauer S, Hartmann G, editors. Toll-Like Receptors (TLRs) and Innate Immunity. Berlin: Springer; 2008:111–127.
   Google Scholar
• Barton GM, Medzhitov R. Toll-like receptor signaling pathways. Science. 2003;300(5625):1524–1525.
   PubMed Web of Science ®Google Scholar
• Wu H, Chen G, Wyburn KR, et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest. 2007;117(10):2847–2859.
   PubMed Web of Science ®Google Scholar
• Strainic MG, Liu J, Huang D, et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity. 2008;28(3):425–435.
   PubMed Web of Science ®Google Scholar
• Vieyra M, Leisman S, Raedler H, et al. Complement regulates CD4 T-cell help to CD8 T cells required for murine allograft rejection. Am J Pathol. 2011;179(2):766–774.
   Web of Science ®Google Scholar
• Cretney E, Kallies A, Nutt SL. Differentiation and function of Foxp3(+) effector regulatory T cells. Trends Immunol. 2013;34(2):74–80.
   PubMed Web of Science ®Google Scholar
• Issa F, Robb RJ, Wood KJ. The where and when of T cell regulation in transplantation. Trends Immunol. 2013;34(3):107–113.
   Web of Science ®Google Scholar
• Murphy SP, Porrett PM., Turka LA. Innate immunity in transplant tolerance and rejection. Immunol Rev. 2011;241(1):39–48.
   Google Scholar
• Patel JK, Kittleson M, Kobashigawa JA. Cardiac allograft rejection. Surgeon. 2011;9(3):160–167.
   PubMed Web of Science ®Google Scholar
• Pikul FJ, Bolman RM, Saffitz JE, Chaplin H. Anti-B-mediated rejection of an ABO-incompatible cardiac allograft despite aggressive plasma exchange transfusion. Transplant Proc. 1987;19(6):4601–4604.
   Web of Science ®Google Scholar
• Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969;280(14):735–739.
   PubMed Web of Science ®Google Scholar
• Terasaki PI. A personal perspective: 100-year history of the humoral theory of transplantation. Transplantation. 2012;93(8):751–756.
   PubMed Web of Science ®Google Scholar
• Bray RA, Nolen JD, Larsen C, et al. Transplanting the highly sensitized patient: the emory algorithm. Am J Transplant. 2006;6(10):2307–2315.
   PubMed Web of Science ®Google Scholar
• Stehlik J, Islam N, Hurst D, et al. Utility of virtual crossmatch in sensitized patients awaiting heart transplantation. J Heart Lung Transplant. 2009;28(11):1129–1134.
   PubMed Web of Science ®Google Scholar
• Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation. 2003;75(1):43–49.
   Web of Science ®Google Scholar
• Cecka JM. Calculated PRA (CPRA):the new measure of sensitization for transplant candidates. Am J Transplant. 2010;10(1):26–29.
   PubMed Web of Science ®Google Scholar
• Kobashigawa J, Mehra M, West L, et al; Consensus Conference Participants. Report from a consensus conference on the sensitized patient awaiting heart transplantation. J Heart Lung Transplant. 2009;28(3):213–225.
   PubMedGoogle Scholar
• Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant. 2012;16(1):12–17.
   PubMed Web of Science ®Google Scholar
• Caves P, Coltart J, Billingham M, Rider A, Stinson E. Transvenous endomyocardial biopsy – application of a method for diagnosing heart disease. Postgrad Med J. 1975;51(595):286–290.
   Web of Science ®Google Scholar
• Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24(11):1710–1720.
   PubMed Web of Science ®Google Scholar
• Jarcho J, Naftel DC, Shroyer TW, et al. Influence of HLA mismatch on rejection after heart transplantation: a multiinstitutional study. The Cardiac Transplant Research Database Group. J Heart Lung Transplant. 1994;13(4):583–595.
   Web of Science ®Google Scholar
• Herskowitz A, Soule LM, Ueda K, et al. Arteriolar vasculitis on endomyocardial biopsy: a histologic predictor of poor outcome in cyclosporine-treated heart transplant recipients. J Heart Transplant. 1987;6(3):127–136.
   Google Scholar
• Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al; Consensus Conference Participants. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2011;30(3):252–269.
   PubMed Web of Science ®Google Scholar
• Berry GJ, Angelini A, Burke MM, et al. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005–2011). J Heart Lung Transplant. 2011;30(6):601–611.
   PubMed Web of Science ®Google Scholar
• Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant. 2011;11(2):312–319.
   PubMed Web of Science ®Google Scholar
• Tambur AR, Pamboukian SV, Costanzo MR, et al. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation. 2005;80(8):1019–1025.
   PubMed Web of Science ®Google Scholar
• Taylor DO, Yowell RL, Kfoury AG, Hammond EH, Renlund DG. Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J Heart Lung Transplant. 2000;19(6):518–521.
   Web of Science ®Google Scholar
• Patel JK, Kobashigawa JA. Improving survival during heart transplantation: diagnosis of antibody-mediated rejection and techniques for the prevention of graft injury. Future Cardiol. 2012;8(4):623–635.
   Google Scholar
• Wu GW, Kobashigawa JA, Fishbein MC, et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant. 2009;28(5):417–422.
   PubMed Web of Science ®Google Scholar
• Mehra MR, Crespo-Leiro MG, Dipchand A, et al. Erratum. J Heart Lung Transplant. 2011;30(3):360.
   Google Scholar
• Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol. 2005;45(9):1532–1537.
   PubMed Web of Science ®Google Scholar
• Fang JC, Kinlay S, Beltrame J, et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet. 2002;359(9312):1108–1113.
   PubMed Web of Science ®Google Scholar
• Romeo G, Houyel L, Angel CY, Brenot P, Riou JY, Paul J. Coronary stenosis detection by 16-slice computed tomography in heart transplant patients: comparison with conventional angiography and impact on clinical management. J Am Coll Cardiol. 2005;45(11):1826–1831.
   Web of Science ®Google Scholar
• Wever-Pinzon O, Romero J, Kelesidis I, et al. Coronary computed tomography angiography for the detection of cardiac allograft vasculopathy: a meta-analysis of prospective trials. J Am Coll Cardiol. 2014;63(19):1992–2004.
   PubMed Web of Science ®Google Scholar
• Kobashigawa J. Coronary computed tomography angiography: is it time to replace the conventional coronary angiogram in heart transplant patients? J Am Coll Cardiol. 2014;63(19):2005–2006.
   PubMed Web of Science ®Google Scholar
• Wu YW, Chen YH, Wang SS, et al. PET assessment of myocardial perfusion reserve inversely correlates with intravascular ultrasound findings in angiographically normal cardiac transplant recipients. J Nucl Med. 2010;51(6):906–912.
   Web of Science ®Google Scholar
• Hou J, Lv H, Jia H, et al. OCT assessment of allograft vasculopathy in heart transplant recipients. JACC Cardiovasc Imaging. 2012;5(6):662–663.
   PubMed Web of Science ®Google Scholar
• Wu YL, Ye Q, Ho C. Cellular and functional imaging of cardiac transplant rejection. Curr Cardiovasc Imaging Rep. 2011;4(1):50–62.
   Google Scholar
• Bader FM, Islam N, Mehta NA, et al. Noninvasive diagnosis of cardiac allograft rejection using echocardiography indices of systolic and diastolic function. Transplant Proc. 2011;43(10):3877–3881.
   PubMed Web of Science ®Google Scholar
• Pham MX, Teuteberg JJ, Kfoury AG, et al; IMAGE Study Group. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med. 2010;362:1890–1900.
   PubMed Web of Science ®Google Scholar
• Pham MX, Deng MC, Kfoury AG, Teuteberg JJ, Starling RC, Valantine H. Molecular testing for long-term rejection surveillance in heart transplant recipients: design of the Invasive Monitoring Attenuation Through Gene Expression (IMAGE) trial. J Heart Lung Transplant. 2007;26(8):808–814.
   PubMed Web of Science ®Google Scholar
• Kobashigawa J, Patel J, Kittleson M, et al. Results of a randomized trial of Allomap vs heart biopsy in the 1st year after heart transplant: early invasive monitoring attenuation through gene expression trial. J Heart Lung Transplant. 2013;32(4):S203.
   Web of Science ®Google Scholar
• Costanzo MR, Dipchand A, Starling R, et al; International Society of Heart and Lung Transplantation Guidelines. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29(8):914–956.
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Kiyosaki KK, Patel JK, et al. Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes. J Heart Lung Transplant. 2010;29(5):504–508.
   Web of Science ®Google Scholar
• Cheng R, Azarbal B, Patel J, Chang D, Kobashigawa J. Elevated immune monitoring after cardiac transplantation is associated with increased plaque progression by intravascular ultrasound. J Am Coll Cardiol. 2014;63(12_S).
   Web of Science ®Google Scholar
• Baran DA, Zucker MJ, Arroyo LH, et al. A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial. Circ Heart Fail. 2011;4(2):129–137.
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA. Strategies in immunosuppression after heart transplantation: is less better? Circ Heart Fail. 2011;4:111–113.
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Miller LW, Russell SD, et al; Study Investigators. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant. 2006;6(6):1377–1386.
   PubMed Web of Science ®Google Scholar
• Andreassen AK, Gude E, Sigurdardottir V, et al. Scandinavian Heart Transplant Everolimus De Novo Study with Early Calcineurin Inhibitor Avoidance (SCHEDULE). J Heart Lung Transplant. 2013;32(4):S134.
   Web of Science ®Google Scholar
• Eisen HJ, Tuzcu EM, Dorent R, et al; RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349(9):847–858.
   PubMed Web of Science ®Google Scholar
• Eisen HJ, Kobashigawa J, Starling RC, et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant. 2013;13(5):1203–1216.
   PubMed Web of Science ®Google Scholar
• Marfo K, Lu A, Ling M, Akalin E. Desensitization protocols and their outcome. Clin J Am Soc Nephrol. 2011;6(4):922–936.
   PubMed Web of Science ®Google Scholar
• Aranda JM Jr, Scornik JC, Normann SJ, et al. Acti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation. 2002;73(6):907–910.
   Web of Science ®Google Scholar
• Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008;86(12):1754–1761.
   PubMed Web of Science ®Google Scholar
• Kittleson MM, Patel JK, Moriguchi JD, et al. Heart transplant recipients supported with extracorporeal membrane oxygenation: outcomes from a single-center experience. J Heart Lung Transplant. 2011;30(11):1250–1256.
   Web of Science ®Google Scholar
• Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008;359:242–251.
   PubMed Web of Science ®Google Scholar
• Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. J Heart Lung Transplant. 2011;30(12):1320–1326.
   PubMed Web of Science ®Google Scholar
• Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant. 2011;11(11):2405–2413.
   PubMed Web of Science ®Google Scholar
• Yousufuddin M, Haji S, Starling RC, et al. Cardiac angiotensin II receptors as predictors of transplant coronary artery disease following heart transplantation. Eur Heart J. 2004;25(5):377–385.
   PubMed Web of Science ®Google Scholar
• Kauke T, Kaczmarek I, Dick A, et al. Anti-MICA antibodies are related to adverse outcome in heart transplant recipients. J Heart Lung Transplant. 2009;28(4):305–311.
   PubMed Web of Science ®Google Scholar
• Qin L, Huang Q, Zhang H, et al. SOCS1 prevents graft arteriosclerosis by preserving endothelial cell function. J Am Coll Cardiol. 2014;63(1):21–29.
   PubMed Web of Science ®Google Scholar
• de Weger RA. Immune regulators regulated to prevent transplant reactions. J Am Coll Cardiol. 2014;63(1):30–32.
   PubMed Web of Science ®Google Scholar
• Chang DH, Kittleson MM, Kobashigawa JA. Immunosuppression following heart transplantation: prospects and challenges. Immunotherapy. 2014;6(2):181–194.
   Web of Science ®Google Scholar
• Berry GC, Burke MM, Andersen C et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2013;32(12):1147–1162.
   PubMed Web of Science ®Google Scholar